ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.294,82
-0,04%
Dow Jones
39.913,10
0,11%
Euro vs US Dollar
1,08683
0,01%
Bitcoin
67.099,37
2,85%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ESSA Pharma Inc (EPIX)

  7. ESSA Pharma Inc (EPIX) News

EPIX

ESSA Pharma (EPIX)

ESSA Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EPIX
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EPIXESSA Pharma Inc
14/05/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EPIXESSA Pharma Inc
14/05/202413h00PR Newswire (US)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024NASDAQ:EPIXESSA Pharma Inc
14/05/202413h00PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024NASDAQ:EPIXESSA Pharma Inc
06/05/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
09/04/202414h00PR Newswire (Canada)ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPIXESSA Pharma Inc
09/04/202414h00PR Newswire (US)ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPIXESSA Pharma Inc
08/03/202402h13PR Newswire (Canada)ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSNASDAQ:EPIXESSA Pharma Inc
08/03/202402h13PR Newswire (US)ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSNASDAQ:EPIXESSA Pharma Inc
07/03/202423h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EPIXESSA Pharma Inc
06/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
13/02/202413h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EPIXESSA Pharma Inc
13/02/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EPIXESSA Pharma Inc
13/02/202413h00PR Newswire (US)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023NASDAQ:EPIXESSA Pharma Inc
13/02/202413h00PR Newswire (Canada)ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023NASDAQ:EPIXESSA Pharma Inc
07/02/202417h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
06/02/202414h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
06/02/202414h00PR Newswire (US)ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:EPIXESSA Pharma Inc
06/02/202414h00PR Newswire (Canada)ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:EPIXESSA Pharma Inc
29/01/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EPIXESSA Pharma Inc
26/01/202422h40Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EPIXESSA Pharma Inc
26/01/202422h27Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EPIXESSA Pharma Inc
25/01/202416h00PR Newswire (Canada)ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumNASDAQ:EPIXESSA Pharma Inc
25/01/202416h00PR Newswire (US)ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumNASDAQ:EPIXESSA Pharma Inc
23/01/202422h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EPIXESSA Pharma Inc
18/01/202402h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
16/01/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EPIXESSA Pharma Inc
16/01/202419h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
09/01/202402h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EPIXESSA Pharma Inc
05/01/202422h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EPIXESSA Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:EPIX

Kürzlich von Ihnen besucht

LSE
CB78
Citi Fun 25
LSE
EN69
Citi Fun 25
BOV
BBASF535
BBASF535 Ex:26,22
BIT
P15IH9
BNP Paribas Issuance
ASX
OSHKOA
USOTC
LTCP
Lifes Time Capsule Servi... (PK)
LSE
0EEZ
Athens Water And Sewerag...
NYSE
CABO
Cable One
USOTC
ARHCF
Alfresa Holdings Corp To... (PK)
LSE
ZYT
Zytronic
BOV
V1NO34
Vornado Realty
LSE
0FBX
Montebalito
BOV
CSRN5
COSERN PNA
CRTO
LOKAUSDT
League of Kingdoms Arena
USOTC
HDALF
Haidilao (PK)
COIN
MEKGBP
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten